Nevirapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Nevirapine: From HIV Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used for HIV-1 infection in humans. The TxGNN model predicts it may be effective for Feline Acquired Immunodeficiency Syndrome, with 0 clinical trials and 1 publication currently supporting this direction. The evidence base remains at preclinical level only, and the indication is veterinary rather than human medicine.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 Infection |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly and non-competitively to HIV-1 reverse transcriptase (RT), blocking both RNA-dependent and DNA-dependent DNA polymerase activity. Unlike nucleoside analogues, it does not require intracellular phosphorylation. Its efficacy against HIV-1 infection is well established in human medicine.
Feline Immunodeficiency Virus (FIV) belongs to the same Lentivirus genus as HIV-1 and causes an acquired immunodeficiency-like syndrome in cats. The theoretical mechanistic basis is that FIV RT shares structural homology with HIV-1 RT, suggesting NNRTIs could potentially bind the FIV RT hydrophobic pocket. However, key residues at the NNRTI binding site of FIV RT — corresponding to critical positions Y181, Y188, and K103 in HIV-1 — differ significantly, resulting in substantially reduced activity for most first-generation NNRTIs including nevirapine.
The TxGNN model’s high score most likely reflects the network connectivity between FIV ↔ HIV-1 ↔ NNRTI nodes in the underlying knowledge graph, rather than direct biological activity. Two additional barriers make this a weak candidate: (1) this is a veterinary indication, governed by a completely separate regulatory and clinical pathway; (2) the single supporting publication is an in vitro structural comparison, not a therapeutic efficacy study.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38031646 | 2023 | In vitro Structural Study | Journal of Veterinary Science | Biochemical and structural comparison of NNRTIs (nevirapine, efavirenz, rilpivirine) against FIV RT vs. HIV RT; investigated the structural basis for differential inhibitor activity between feline and human lentiviral reverse transcriptases |
Safety Considerations
Drug Interactions: Nevirapine has 207 known drug interactions (source: DDInter). The following moderate-level interactions are representative:
| Interacting Drug | Level | Clinical Relevance |
|---|---|---|
| Clarithromycin | Moderate | CYP3A4 interaction; may alter nevirapine plasma levels |
| Dexamethasone | Moderate | CYP3A4 induction; may reduce nevirapine exposure |
| Betamethasone | Moderate | CYP3A4 interaction |
| Budesonide | Moderate | CYP3A4 interaction |
| Triamcinolone | Moderate | CYP3A4 interaction |
| Prednisolone | Moderate | CYP3A4 interaction |
| Bupropion | Moderate | CYP2B6 substrate; nevirapine is a CYP2B6 inducer |
| Ondansetron | Moderate | CYP3A4 interaction |
| Granisetron | Moderate | CYP3A4 interaction |
| Aprepitant | Moderate | CYP3A4 interaction |
| Saxagliptin | Moderate | CYP3A4/5 substrate |
| Linagliptin | Moderate | CYP3A4 interaction |
| Naltrexone | Moderate | CYP3A4 interaction |
| Naloxegol | Moderate | CYP3A4 substrate |
| Naldemedine | Moderate | CYP3A4 substrate |
| Cisapride | Moderate | CYP3A4 substrate |
| Eliglustat | Moderate | CYP2D6/CYP3A4 substrate |
| Orlistat | Moderate | May reduce oral bioavailability |
| Nitisinone | Moderate | CYP-mediated interaction |
| Rabeprazole | Moderate | CYP2C19 interaction |
Please refer to the package insert for key warnings and contraindications (data not available in this evidence pack).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN prediction connects Nevirapine to feline acquired immunodeficiency syndrome via knowledge graph network paths, but the evidence base is limited to a single in vitro structural study with no clinical trial data; furthermore, the target indication is veterinary medicine, which lies outside the standard human drug repurposing pathway.
To proceed, the following is needed:
- In vitro antiviral activity data specifically confirming nevirapine efficacy against wild-type FIV reverse transcriptase (not just structural modelling)
- Clarification of development intent: veterinary medicine vs. human medicine repurposing
- MOA data from DrugBank to complete the mechanistic analysis (DG002)
- Key warnings and contraindications from the package insert (DG001) before any safety evaluation
- If veterinary development is intended: regulatory pathway assessment under applicable veterinary drug approval frameworks
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.